Financial Instruments (Narrative) (Details)	3 Months Ended
	Mar. 31, 2026 USD ($)	Mar. 31, 2025 USD ($)	Dec. 31, 2025 USD ($)	Sep. 02, 2020 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Realized investment gains (losses)	$ 0	$ 0
Change in fair value of contingent consideration	1,740,000	(2,830,000)
Current portion of contingent consideration	21,490,000		$ 20,690,000
Ascyrus Medical LLC
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of outstanding equity acquired				100.00%
Maximum amount of future consideration payment				$ 100,000,000.0
Change in fair value of contingent consideration	1,700,000	$ (2,800,000)
Business combination, contingent consideration, liability	62,300,000		$ 60,600,000
Current portion of contingent consideration	21,500,000
Ascyrus Medical LLC | Contingent Payment Upon PMA Approval
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability	$ 25,000,000.0
Ascyrus Medical LLC | Measurement Input, Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, measurement input	0.17